Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Urogen Pharma (URGN) had Return on Tangible Equity of 53.48% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$24.21M |
|
$-49.94M |
|
$3.55M |
|
$20.66M |
|
$65.66M |
|
$-41.45M |
|
$-7.48M |
|
$-48.92M |
|
$-48.92M |
|
$-49.94M |
|
$-49.94M |
|
$-49.94M |
|
$-49.94M |
|
$-41.45M |
|
$-42.23M |
|
47.74M |
|
47.74M |
|
$-1.05 |
|
$-1.05 |
|
| Balance Sheet Financials | |
$196.87M |
|
$0.69M |
|
$11.85M |
|
$208.72M |
|
$47.55M |
|
$122.51M |
|
$254.54M |
|
$302.09M |
|
$-93.38M |
|
$-93.38M |
|
$-93.38M |
|
46.20M |
|
| Cash Flow Statement Financials | |
$-81.85M |
|
$2.44M |
|
$0.33M |
|
$173.06M |
|
$93.99M |
|
$-79.08M |
|
$5.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.14 |
|
-- |
|
-- |
|
4.21 |
|
-1.31 |
|
85.34% |
|
-171.17% |
|
-171.17% |
|
-- |
|
-202.04% |
|
-206.24% |
|
$-82.03M |
|
-- |
|
-- |
|
-- |
|
0.12 |
|
0.50 |
|
1.23 |
|
73.03 |
|
53.48% |
|
|
Return on Tangible Equity |
53.48% |
-23.93% |
|
-171.43% |
|
$-2.02 |
|
$-1.72 |
|
$-1.71 |
|